Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Genotype-phenotype associations in PPGLs in 59 patients with variants in SDHX genes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Levels of endocrine-disrupting chemicals are associated with changes in the peri-pubertal epigenome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Role of fasting duration and weekday in incretin and glucose regulation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Association Between Elevated suPAR, a New Biomarker of Inflammation, and Accelerated Aging

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Validation of suPAR turbidimetric assay on Cobas® (c502 and c702) and comparison to suPAR ELISA

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Growth hormone deficiency (GHD) syndrome is associated with adverse levels of several risk factors for cardiovascular diseases (CVD), including metabolic inflammation. However, the impact of GHD and GH treatment on low-grade inflammation is unknown. The aim of the study was to establish the level of the low-grade inflammation biomarker soluble urokinase plasminogen activator receptor (suPAR) in adults with GHD and the response to long-term GH treatment. Measurements of suPAR and CRP were performed in bio-bank serum samples from 72 adults, 34 males and 38 females, with GHD before and during at least 5 years of GH treatment. Mean age was 52.5 ± 15.5 years, BMI 27.3 ± 5 kg/m2. Clinical evaluations and blood sampling were performed at routine visits. Data on demography, anthropometry, lab results and clinical events were retrieved from post-marketing surveillance study databases and medical records. suPAR and high-sensitive (hs) CRP were analysed using ELISA and immunochemistry, respectively. At baseline blood pressure, lipid profile and fasting glucose were within the normal reference range. Baseline geometric mean and 95% CI of suPAR was 2.9 (2.7-3.3) ng/mL and of CRP 2.3 (0.6-4.0) mg/L. Mean follow-up was 8 ± 2 years. The suPAR levels remained stable during follow-up, although individual increases were seen on occurrence or presence of co-morbidities. In contrast, levels of CRP decreased. In conclusion, the decrease in CRP and indirectly the absence of an expected increase in suPAR over time indicates a favourable effect of GH on low-grade inflammation.

OriginalsprogEngelsk
TidsskriftEndocrine Connections
Vol/bind8
Udgave nummer6
Sider (fra-til)772-779
Antal sider8
ISSN2049-3614
DOI
StatusUdgivet - 1 jun. 2019

ID: 57307125